This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
To streamline complex medical writing workflows with GenAI
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
Subscribe To Our Newsletter & Stay Updated
